Table 1 Patient characteristics at baseline
Case number | 78 patients |
|---|---|
Sex (male/female) | 50/28 |
Age (years) | 70 (20–87) |
APACHE II score | 24 (3–38) |
SOFA score | 11 (0–19) |
MAP before the PMX treatment (mmHg) | 64 (40–104) |
CVP before the PMX treatment (mmHg) | 15 (12–22) |
Creatinine before the PMX treatment (mg/dl) | 1.42 (0.41–10.24) |
Endotoxin level before the PMX treatment (pg/mL) | 11.3 (0.8–1925) |
Lactate level before the PMX treatment (mmol/L) | 3.7 (1.0–23.0) |
Patients with diabetes mellitus | 24 |
Patients received corticosteroid therapy | 13 |
The times of PMX therapy | 1 (1–6) |
Total PMX treatment time (min) | 1456 (80–18,100) |
Suspected causative microorganisms | |
GNR | 41 |
GPC | 12 |
GPR | 2 |
Unknown origin | 23 |
Infection site | |
Abdomen | 27 |
Bloodstream | 15 |
Lung | 10 |
Urinary tract | 6 |
Others (unknown origin) | 20 |